Fresenius Medical Care AG (FME.DE)
| Previous Close | 39.18 |
| Open | 39.37 |
| Bid | 39.14 x 38700 |
| Ask | 39.14 x 105300 |
| Day's Range | 38.96 - 39.86 |
| 52 Week Range | 30.16 - 49.62 |
| Volume | |
| Avg. Volume | 463,367 |
| Market Cap | 11.478B |
| Beta (5Y Monthly) | 0.90 |
| PE Ratio (TTM) | 23.71 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.19 (3.04%) |
| Ex-Dividend Date | May 17, 2024 |
| 1y Target Est | N/A |
- PR Newswire
Moody's and S&P change Fresenius Medical Care's rating outlook to stable
Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today received from S&P Global, a leading rating agency, the change of its rating outlook to stable from negative (bbb-, stable outlook). Moody's changed the credit rating outlook from negative to stable on May 17 (baa3, stable outlook).
- PR Newswire
Fresenius Medical Care showcases leadership and innovation in kidney care disease at 61st European Renal Association (ERA) Congress 2024
Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the presentation of nearly 40 company-affiliated research abstracts at the 61st European Renal Association (ERA) Congress, taking place May 23-26, 2024, in Stockholm, Sweden and virtually.
- PR Newswire
Fresenius Medical Care Annual General Meeting: Company makes significant progress in its Transformation Efforts and confirms its ambitious 2024 Growth Targets
Fresenius Medical Care (FME), the global leader in providing products and services for people with kidney diseases, is executing its strategic turnaround plan and is well on track to achieve its goals for 2024.
